Patents by Inventor John King-Underwood

John King-Underwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
    Patent number: 9475796
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: October 25, 2016
    Assignee: Respivert Limited
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • Inhibitor of p38 map kinase
    Patent number: 9447076
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 20, 2016
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • COMPOUNDS
    Publication number: 20160264583
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Application
    Filed: March 31, 2016
    Publication date: September 15, 2016
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS
    Publication number: 20160222019
    Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors
    Patent number: 9340545
    Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: May 17, 2016
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • NOVEL COMPOUNDS
    Publication number: 20160130256
    Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.
    Type: Application
    Filed: January 18, 2016
    Publication date: May 12, 2016
    Applicant: Respivert Limited
    Inventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • Novel Compounds
    Publication number: 20160115152
    Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.
    Type: Application
    Filed: January 6, 2016
    Publication date: April 28, 2016
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Ito Kazuhiro, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • Compounds
    Patent number: 9321773
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 26, 2016
    Assignee: Respivert, Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • P38 MAP kinase inhibitors
    Patent number: 9260410
    Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: February 16, 2016
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • Pyrazole derivatives as p38 MAP inhibitors
    Patent number: 9249125
    Abstract: Compounds of formula (I): wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: February 2, 2016
    Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITED
    Inventors: Lorna Anne Duffy, John King-Underwood, Alistair Ian Longshaw, Peter John Murray, Stuart Thomas Onions, David Michael Adrien Taddei, Jonathan Gareth Williams, Kazuhiro Ito, Catherine Elisabeth Charron
  • P38MAP kinase inhibitors
    Patent number: 9242960
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: January 26, 2016
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Onions, Catherine Elisabeth Charron
  • 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- I - YL) UREAS AS P38 MAPKINASE INHIBITORS
    Publication number: 20160009695
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 14, 2016
    Applicant: RESPIVERT LTD.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • 1-PYRAZOLYL-3-((4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS
    Publication number: 20150252024
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 10, 2015
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20150232450
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Application
    Filed: February 13, 2015
    Publication date: August 20, 2015
    Inventors: ALISTAIR IAN LONGSHAW, EUAN ALEXANDER FRASER FORDYCE, STUART THOMAS ONIONS, JOHN KING-UNDERWOOD, JENNIFER VENABLE
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
    Patent number: 9108950
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: August 18, 2015
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • PYRAZOLYL-UREAS AS KINASE INHIBITORS
    Publication number: 20150218137
    Abstract: There are provided compounds of formula I, wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Application
    Filed: August 16, 2013
    Publication date: August 6, 2015
    Inventors: Claire Anne Marie Cariou, Catherine Elisabeth Charron, Euan Alexander Fraser Fordyce, Daniel Hamza, Matthew Colin Thor Fyfe, Kazuhiro Ito, John King-Underwood, Peter John Murray, Stuart Thomas Onions, Stephen Malcolm Thom, Hayley Tegan Angela Watson, Jonathan Gareth Williams
  • PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS
    Publication number: 20150203475
    Abstract: Compounds of formula (I): wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.
    Type: Application
    Filed: August 28, 2013
    Publication date: July 23, 2015
    Applicant: TOPIVERT PHARMA LIMITED
    Inventors: Lorna Anne Duffy, John King-Underwood, Alistair Ian Longshaw, Peter John Murray, Stuart Thomas Onions, David Michael Adrien Taddei, Jonathan Gareth Williams, Kazuhiro Ito, Catherine Elisabeth Charron
  • P38 MAP kinase inhibitors
    Patent number: 9024041
    Abstract: There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: May 5, 2015
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Peter John Murray, Jonathan Gareth Williams, Ildiko Buck, Stuart Thomas Onions
  • P38 MAP kinase inhibitors
    Patent number: 8975285
    Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: March 10, 2015
    Assignee: Respivert Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
  • 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1- YL) UREAS AS P38 MAP KINASE INHIBITORS
    Publication number: 20140249169
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 4, 2014
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans